Please login to the form below

Not currently logged in
Email:
Password:

Tofersen

This page shows the latest Tofersen news and features for those working in and with pharma, biotech and healthcare.

Biogen’s R&D chief Ehlers heads for the exit

Biogen’s R&D chief Ehlers heads for the exit

There’s still plenty in the neuroscience pipeline however, including  tofersen for amyotrophic lateral sclerosis (ALS) which stems from an alliance with antisense specialist Ionis and is due for a phase

Latest news

  • Biogen’s tofersen shows promise in slowing down ALS Biogen’s tofersen shows promise in slowing down ALS

    Hope for subset of patients with wasting disease. Biogen has revealed promising preliminary data for tofersen, a potential treatment for the fatal neurodegenerative disease amyotrophic lateral sclerosis (ALS). ... Tofersen is just one of seven candidates

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics